Chieh‐Lung Cheng

515 total citations
23 papers, 334 citations indexed

About

Chieh‐Lung Cheng is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Chieh‐Lung Cheng has authored 23 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Epidemiology. Recurrent topics in Chieh‐Lung Cheng's work include Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (6 papers) and Acute Myeloid Leukemia Research (4 papers). Chieh‐Lung Cheng is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (6 papers) and Acute Myeloid Leukemia Research (4 papers). Chieh‐Lung Cheng collaborates with scholars based in Taiwan, United States and Czechia. Chieh‐Lung Cheng's co-authors include Hwei‐Fang Tien, Ming Yao, Jih‐Luh Tang, Hsin‐An Hou, Wen‐Chien Chou, Woei Tsay, Shang‐Yi Huang, Bor‐Sheng Ko, Shang‐Ju Wu and Chung‐Wu Lin and has published in prestigious journals such as Blood, British Journal of Cancer and The American Journal of Surgical Pathology.

In The Last Decade

Chieh‐Lung Cheng

20 papers receiving 328 citations

Peers

Chieh‐Lung Cheng
Tobias Terzer Germany
Carlos Aguilar Spain
Jie Peng China
Qizhe Cai China
Rony Abou Jawde United States
A Kapelle Germany
Daniele Compagnone Germany
Larisa Dzirlo Austria
Theodoros Kassimatis Greece
Christos Bantis Germany
Tobias Terzer Germany
Chieh‐Lung Cheng
Citations per year, relative to Chieh‐Lung Cheng Chieh‐Lung Cheng (= 1×) peers Tobias Terzer

Countries citing papers authored by Chieh‐Lung Cheng

Since Specialization
Citations

This map shows the geographic impact of Chieh‐Lung Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chieh‐Lung Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chieh‐Lung Cheng more than expected).

Fields of papers citing papers by Chieh‐Lung Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chieh‐Lung Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chieh‐Lung Cheng. The network helps show where Chieh‐Lung Cheng may publish in the future.

Co-authorship network of co-authors of Chieh‐Lung Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Chieh‐Lung Cheng. A scholar is included among the top collaborators of Chieh‐Lung Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chieh‐Lung Cheng. Chieh‐Lung Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Chieh‐Lung, et al.. (2025). Aortic mural thrombosis with bilateral renal infarction in a woman taking dienogest for adenomyosis: A case report and literature review. Taiwanese Journal of Obstetrics and Gynecology. 64(5). 842–846.
2.
Cheng, Chieh‐Lung, You‐Yu Lin, Chia‐Lang Hsu, et al.. (2024). Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis. British Journal of Cancer. 131(6). 996–1004. 2 indexed citations
3.
4.
Cheng, Chieh‐Lung, Po‐Ting Yeh, Weili Ma, et al.. (2023). Long‐term outcomes of combined intravitreal methotrexate and systemic high‐dose methotrexate therapy in vitreoretinal lymphoma. Cancer Medicine. 12(7). 8102–8111. 4 indexed citations
5.
Cheng, Chieh‐Lung, et al.. (2022). Bone Marrow Histology in Hemophagocytic Lymphohistiocytosis. Archives of Pathology & Laboratory Medicine. 147(3). 348–358. 3 indexed citations
6.
Cheng, Chieh‐Lung, Chi‐Yuan Yao, Chih‐Wei Yu, et al.. (2022). Cerebrospinal fluid soluble programmed death‐ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. British Journal of Haematology. 201(1). 75–85. 3 indexed citations
7.
Cheng, Chieh‐Lung, et al.. (2021). Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. Journal of Cancer Research and Clinical Oncology. 148(5). 1211–1222. 4 indexed citations
8.
Wang, Yuwen, Cheng‐Hong Tsai, Hsin‐An Hou, et al.. (2021). Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology. 101(2). 349–358. 15 indexed citations
9.
Teng, Shu‐Chun, Tai‐Chung Huang, Chieh‐Lung Cheng, et al.. (2021). A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein–Barr Virus. Infectious Diseases and Therapy. 10(4). 2661–2675. 3 indexed citations
10.
Wang, Yuwen, Cheng‐Hong Tsai, Chien‐Chin Lin, et al.. (2020). Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Annals of Hematology. 99(3). 501–511. 55 indexed citations
11.
Cheng, Chieh‐Lung, Jia‐Hong Chen, Tung‐Hung Su, et al.. (2020). Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. The Oncologist. 25(9). 793–802. 15 indexed citations
12.
Tsai, Cheng‐Hong, Hsin‐An Hou, Jia‐Hau Liu, et al.. (2020). Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 12–12. 2 indexed citations
13.
14.
Cheng, Chieh‐Lung, et al.. (2018). Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B‐cell lymphoma. European Journal Of Haematology. 101(1). 28–37. 7 indexed citations
15.
Huang, Shang‐Yi, Hsiu‐Hsia Lin, Chung‐Wu Lin, et al.. (2016). Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 7(38). 62490–62502. 25 indexed citations
16.
Cheng, Chieh‐Lung, Chi-Cheng Li, Hsin‐An Hou, et al.. (2015). Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 15(1). 344–344. 43 indexed citations
17.
Cheng, Chieh‐Lung, Hsin‐An Hou, Chieh‐Yu Liu, et al.. (2013). Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood. 121(16). 3172–3180. 47 indexed citations
18.
Cheng, Chieh‐Lung, Hsin‐An Hou, Chung‐Wu Lin, et al.. (2011). High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. British Journal of Cancer. 105(7). 975–982. 20 indexed citations
19.
Wu, Cho‐Kai, Chia‐Ti Tsai, Yao-Ting Huang, et al.. (2009). Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The Pharmacogenomics Journal. 10(1). 46–53. 33 indexed citations
20.
Cheng, Chieh‐Lung, et al.. (1998). Incidental renal cell carcinoma: pathologic features and survival rate.. PubMed. 61(2). 71–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias Terzer Breakdown of academic impact, for papers by Carlos Aguilar Breakdown of academic impact, for papers by Jie Peng Breakdown of academic impact, for papers by Qizhe Cai Breakdown of academic impact, for papers by Rony Abou Jawde Breakdown of academic impact, for papers by A Kapelle Breakdown of academic impact, for papers by Daniele Compagnone Breakdown of academic impact, for papers by Larisa Dzirlo Breakdown of academic impact, for papers by Theodoros Kassimatis Breakdown of academic impact, for papers by Christos Bantis
Rankless by CCL
2026